ANAHEIM, CA — Switching to clopidogrel postdischarge after starting on a more potent P2Y12 inhibitor as part of dual antiplatelet therapy (DAPT) after primary PCI apparently doesn't lead to a greater ...
ANAHEIM, CA—Patients undergoing PCI for acute myocardial infarction have equivalent clinical outcomes at 1 year no matter whether they are treated with prasugrel (Effient; Eli Lilly) or ticagrelor ...
ROME, Italy—The choice of prasugrel or ticagrelor for patients with acute MI undergoing primary PCI may make little difference, at least in the short term, suggest results from the PRAGUE-18 trial. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback